Patients and policymakers hoped to see lower health care costs from the Inflation Reduction Act. But unintended consequences, such as limited treatment options and stifled innovation, affect cardiovascular patients’ access to the treatments they need.
Medical innovation like genetically targeted technologies powers the next generation of treatments and cures. Treatments like GTTs use Nobel prize-winning science and can reduce patients’ number of pharmacy visits, simplify medication routines, and ultimately improve patients’ heart health management.
But for more patients to benefit, Congress needs to pass the bipartisan MINI Act. This legislation allows more time for research, investment and infrastructure for genetically targeted technologies. Tell your representatives: Pass the MINI Act.